{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:38:19Z","timestamp":1790854699136,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>HCV treatment has been revolutionized by introduction of direct-acting antiviral therapy (DAA). Short treatment duration of eight to twelve weeks combined with significantly improved tolerability opened the opportunity to reach out to difficult-to-treat populations. Here, we retrospectively analyzed <jats:italic>real life<\/jats:italic> data on HCV treatment adherence and outcome in people who inject drugs (PWID) or on opioid substitution therapy (OST).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>All PWID or on OST receiving DAA therapy between 3\/2021\u201311\/2022 at an infectious disease clinic in Bonn were retrospectively analyzed. Patients received either 8\u00a0weeks glecaprevir\/pibrentasvir or 12\u00a0weeks sofosbuvir\/velpatasvir (+\u2009ribavirin in genotype 3 cirrhotic patients). Sustained virological response (SVR) was measured 4 and 12\u00a0weeks after HCV therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In our cohort 47 patients (68%) received treatment with glecaprevir\/pibrentasvir and 22 patients (32%) sofosbuvir\/velpatasvir. All 47 (100%) patients started on glecaprevir\/pibrentasvir received prescriptions for the full length of therapy, while patients on sofosbuvir\/velpatasvir completed 12\u00a0weeks therapy in 86% and 8\u00a0weeks in 14% (p\u2009=\u20090.029).<\/jats:p>\n            <jats:p>Of 69 patients 74% were found to achieve SVR. In 20% no information is available as they were lost to follow-up. Re-infection was documented in 3 patients and one relapse in a gt3 patient with cirrhosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>High adherence and response rates to HCV treatment were found following DAA based therapy in PWID supporting the call to include difficult-to-treat populations into HCV treatment efforts on the way to HCV elimination. Treatment of OST and HCV at one institution supporting patients by a multidisciplinary team may further facilitate adherence to follow up visits enabling documentation of treatment outcomes more easily.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s15010-024-02433-4","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T09:04:37Z","timestamp":1731315877000},"page":"1205-1211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-life data of hepatitis C treatment with direct acting antiviral therapy in persons injecting drugs or on opioid substitution therapy"],"prefix":"10.1007","volume":"53","author":[{"given":"Pfaeffle","family":"M.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duenkelmann","family":"S.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boesecke","family":"C","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rockstroh","family":"J.K.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Schwarze-Zander","family":"C.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"2433_CR1","volume-title":"Global Hepatitis Report","author":"WHO","year":"2017","unstructured":"WHO. Global Hepatitis Report. NY: World Health Organization; 2017."},{"issue":"12","key":"2433_CR2","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207. https:\/\/doi.org\/10.1016\/S2214-109X(17)30375-3.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"2433_CR3","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1186\/s12889-016-3545-4","volume":"16","author":"B Wenz","year":"2016","unstructured":"Wenz B, Nielsen S, Gassowski M, Santos-Hovener C, Cai W, Ross RS, et al. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011\u201314). BMC Public Health. 2016;16(1):927. https:\/\/doi.org\/10.1186\/s12889-016-3545-4.","journal-title":"BMC Public Health"},{"issue":"12","key":"2433_CR4","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","volume":"29","author":"L Sandrin","year":"2003","unstructured":"Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705\u201313. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2003.07.001.","journal-title":"Ultrasound Med Biol"},{"issue":"5","key":"2433_CR5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/add.14128","volume":"113","author":"S Christensen","year":"2018","unstructured":"Christensen S, Buggisch P, Mauss S, Boker KHW, Schott E, Klinker H, et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice? Addiction. 2018;113(5):868\u201382. https:\/\/doi.org\/10.1111\/add.14128.","journal-title":"Addiction"},{"issue":"1","key":"2433_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12954-023-00774-1","volume":"20","author":"H St\u00f6ver","year":"2023","unstructured":"St\u00f6ver H, Dichtl A, Sch\u00e4ffer D, Grabski M. HIV and HCV among drug users and people living in prisons in Germany 2022: WHO elimination targets as reflected in practice. Harm Reduct J. 2023;20(1):50. https:\/\/doi.org\/10.1186\/s12954-023-00774-1.","journal-title":"Harm Reduct J"},{"issue":"3","key":"2433_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","volume":"3","author":"J Grebely","year":"2018","unstructured":"Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3(3):153\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(17)30404-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"2433_CR8","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1007\/s12325-023-02539-5","volume":"40","author":"A Martinez","year":"2023","unstructured":"Martinez A, Cheng WH, Marx SE, Manthena S, Dylla DE, Wilson L, et al. Shorter duration hepatitis C virus treatment is associated with better persistence to prescription refills in people who inject drugs: A real-world study. Adv Ther. 2023;40(8):3465\u201377. https:\/\/doi.org\/10.1007\/s12325-023-02539-5.","journal-title":"Adv Ther"},{"key":"2433_CR9","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.dadr.2023.100213","volume":"10","author":"JI Tsui","year":"2024","unstructured":"Tsui JI, Gojic AJ, Pierce KA, Tung EL, Connolly NC, Radick AC, et al. Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. Drug Alcohol Depend Rep. 2024;10:100213. https:\/\/doi.org\/10.1016\/j.dadr.2023.100213.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"4","key":"2433_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","volume":"7","author":"SS Solomon","year":"2022","unstructured":"Solomon SS, Wagner-Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, et al. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022;7(4):307\u201317. https:\/\/doi.org\/10.1016\/S2468-1253(21)00397-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"2433_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/cid\/cix126","volume":"64","author":"J Young","year":"2017","unstructured":"Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, et al. Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV. Clin Infect Dis. 2017;64(9):1154\u201362. https:\/\/doi.org\/10.1093\/cid\/cix126.","journal-title":"Clin Infect Dis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02433-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:54:28Z","timestamp":1749016468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02433-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2433"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02433-4","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MP has no conflict of interest or personal relationships that could have influenced any aspects of this work. SD has received study grants from AbbVie and ViiV Healthcare. CB has received honoraria for lectures and\/or consultancies from AbbVie, Astra Zeneca, Bavarian Nordic, Gilead Sciences, Janssen, MSD, Pfizer, ViiV. CSZ has received study grants and attended advisory boards for AbbVie, ViiV Healthcare, Gilead Sciences, Janssen, and Merck. JKR has received honoraria for participating in advisory boards and speaking at educational events from AbbVie, Gilead Sciences, Janssen,","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was performed in accordance with local institutional review board (IRB) guidelines of the University of Bonn (267\/22).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The institutional review board (IRB) of University Bonn, Germany, approved this study (Nr. 267\/22).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and consent to publish:"}}]}}